S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley (2013/4/4)|
|Regeneron Reports First Quarter 2013 Financial and Operating Results (2013/5/3)|
|Regeneron Announces Potential Additional Royalty Stream Related to EU Approval for Ilaris® (canakinumab) in Patients Suffering Acute Gouty Arthritis Attacks Who Cannot Gain Relief From Current Treatments (2013/3/4)|
|Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs (2013/5/3)|
|Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013 (2013/4/11)|
|Regeneron Announces Upcoming 2013 Investor Conference Presentations (2013/4/18)|
|Regeneron Pharmaceuticals Co-Founder Receives $81.55 Million Compensation (2013/4/29)|
|PULSE: Regeneron shares jump on Sanofi share buy plan (2013/2/11)|
|Regeneron to Join S&P 500 After MetroPCS Merger with T-Mobile (2013/4/24)|
|Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis (2013/3/2)|
Click above to view more mutual fund data and stats for regn - Regeneron Pharmaceuticals, Inc..